To assess the safety, tolerability and pharmacokinetics of AZD5634 following inhaled and intravenous (IV)dose administration

Trial Identifier: D6600C00001
Sponsor: AstraZeneca
NCTID:: NCT02679729
Start Date: February 2016
Primary Completion Date: October 2016
Condition: Cystic Fibrosis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
United States of America, CA Glendale, CA, United States of America, 91206
United States of America, MD Baltimore, MD, United States of America, 21225